Bone Parameters are Improved with Intermittent Dosing of Vitamin D3 and Calcitonin
Authors:
- 18 November 2008
- journal article
- research article
- Published by Springer Nature in Calcified Tissue International
- Vol. 83 (6) , 393-403
Abstract
Intermittent combination of an anabolic agent to promote bone formation and an antiresorptive agent that would prevent further bone loss is a theoretically attractive approach for restoring bone mass. We tested the potential of intermittently dosed calcitriol and calcitonin (CT) to restore bone properties in ovariectomized (Ovx) rats. Rats had Ovx or sham surgery at 8 weeks old and 4 weeks later were assigned to experimental groups: (1) sham vehicle, (2) Ovx vehicle, (3) Ovx + parathyroid hormone (PTH, 40 μg/kg), and (4) Ovx + calcitriol (2 μg/kg) + CT (2 μg/kg). Group 3 received PTH every week throughout the study, and group 4 received calcitriol at weeks 1, 3, 5, and 7 and CT at weeks 2, 4, 6, and 8. Dosing was carried out for 8 weeks with serum, and micro-computed tomographic analysis was done at 0, 4, and 8 weeks. Femurs and tibias were used for radiological analyses and for mechanical testing. Dosing with PTH improved bone mass and structure of cancellous bone at metaphyses of tibias and femurs as well as properties of cortical bone including geometry and strength. Intermittent dosing with calcitriol and CT was less potent in correcting loss of cancellous bone relative to treatment with PTH and had no effect on cortical bone parameters. However, intermittent dosing with calcitriol and CT was robust enough to improve cancellous bone mass and structure through bone formation without causing deleterious side effects. Our data provide additional evidence that therapies can be devised to ameliorate the skeletal defects associated with established osteoporosis.Keywords
This publication has 45 references indexed in Scilit:
- Mineralization, microdamage, and matrix: How bisphosphonates influence material properties of boneBoneKEy Reports, 2007
- New nonsteroidal vitamin D receptor modulators: Are these ligands the real deal?BoneKEy Reports, 2006
- One Year of Alendronate after One Year of Parathyroid Hormone (1–84) for OsteoporosisNew England Journal of Medicine, 2005
- The Effects of Parathyroid Hormone, Alendronate, or Both in Men with OsteoporosisNew England Journal of Medicine, 2003
- The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal OsteoporosisNew England Journal of Medicine, 2003
- The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?Bone, 1995
- Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized ratsBone, 1995
- The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats.Endocrinology, 1993
- Vitamin D3and Calcium to Prevent Hip Fractures in Elderly WomenNew England Journal of Medicine, 1992
- The Effect of Calcitriol on Patients with Postmenopausal Osteoporosis with Special Reference to Fracture FrequencyExperimental Biology and Medicine, 1989